Report cover image

Global IL-17 Inhibitors for Psoriasis Market Analysis and Forecast 2025-2031

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 192 Pages
SKU # APRC20283155

Description

Summary

According to APO Research, The global IL-17 Inhibitors for Psoriasis market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for IL-17 Inhibitors for Psoriasis is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of IL-17 Inhibitors for Psoriasis include UCB, Kyowa Kirin, LEO Pharma, Ortho Dermatologics, Jiangsu Hengrui Pharmaceuticals, Eli Lilly, Novartis and Chongqing Genrix Biopharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for IL-17 Inhibitors for Psoriasis, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of IL-17 Inhibitors for Psoriasis, also provides the sales of main regions and countries. Of the upcoming market potential for IL-17 Inhibitors for Psoriasis, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the IL-17 Inhibitors for Psoriasis sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global IL-17 Inhibitors for Psoriasis market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for IL-17 Inhibitors for Psoriasis sales, projected growth trends, production technology, application and end-user industry.

IL-17 Inhibitors for Psoriasis Segment by Company

UCB
Kyowa Kirin
LEO Pharma
Ortho Dermatologics
Jiangsu Hengrui Pharmaceuticals
Eli Lilly
Novartis
Chongqing Genrix Biopharmaceutical
IL-17 Inhibitors for Psoriasis Segment by Type

Ixekizumab
Secukinumab
Xeligekimab
Vunakizumab
Brodalumab
Bimelizumab
Other
IL-17 Inhibitors for Psoriasis Segment by Application

Hospital and Clinic
Pharmacy
Other
IL-17 Inhibitors for Psoriasis Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global IL-17 Inhibitors for Psoriasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of IL-17 Inhibitors for Psoriasis and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of IL-17 Inhibitors for Psoriasis.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of IL-17 Inhibitors for Psoriasis in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of IL-17 Inhibitors for Psoriasis manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IL-17 Inhibitors for Psoriasis sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 IL-17 Inhibitors for Psoriasis Market by Type
1.2.1 Global IL-17 Inhibitors for Psoriasis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Ixekizumab
1.2.3 Secukinumab
1.2.4 Xeligekimab
1.2.5 Vunakizumab
1.2.6 Brodalumab
1.2.7 Bimelizumab
1.2.8 Other
1.3 IL-17 Inhibitors for Psoriasis Market by Application
1.3.1 Global IL-17 Inhibitors for Psoriasis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital and Clinic
1.3.3 Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 IL-17 Inhibitors for Psoriasis Market Dynamics
2.1 IL-17 Inhibitors for Psoriasis Industry Trends
2.2 IL-17 Inhibitors for Psoriasis Industry Drivers
2.3 IL-17 Inhibitors for Psoriasis Industry Opportunities and Challenges
2.4 IL-17 Inhibitors for Psoriasis Industry Restraints
3 Global Market Growth Prospects
3.1 Global IL-17 Inhibitors for Psoriasis Revenue Estimates and Forecasts (2020-2031)
3.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region
3.2.1 Global IL-17 Inhibitors for Psoriasis Revenue by Region: 2020 VS 2024 VS 2031
3.2.2 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2020-2025)
3.2.3 Global IL-17 Inhibitors for Psoriasis Revenue by Region (2026-2031)
3.2.4 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Region (2020-2031)
3.3 Global IL-17 Inhibitors for Psoriasis Sales Estimates and Forecasts 2020-2031
3.4 Global IL-17 Inhibitors for Psoriasis Sales by Region
3.4.1 Global IL-17 Inhibitors for Psoriasis Sales by Region: 2020 VS 2024 VS 2031
3.4.2 Global IL-17 Inhibitors for Psoriasis Sales by Region (2020-2025)
3.4.3 Global IL-17 Inhibitors for Psoriasis Sales by Region (2026-2031)
3.4.4 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Region (2020-2031)
3.5 US & Canada & Mexico
3.6 Europe
3.7 China
3.8 Asia (Excluding China)
3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
4.1 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers
4.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Manufacturers (2020-2025)
4.1.2 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Manufacturers (2020-2025)
4.1.3 Global IL-17 Inhibitors for Psoriasis Manufacturers Revenue Share Top 10 and Top 5 in 2024
4.2 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers
4.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Manufacturers (2020-2025)
4.2.2 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Manufacturers (2020-2025)
4.2.3 Global IL-17 Inhibitors for Psoriasis Manufacturers Sales Share Top 10 and Top 5 in 2024
4.3 Global IL-17 Inhibitors for Psoriasis Sales Price by Manufacturers (2020-2025)
4.4 Global IL-17 Inhibitors for Psoriasis Key Manufacturers Ranking, 2023 VS 2024 VS 2025
4.5 Global IL-17 Inhibitors for Psoriasis Key Manufacturers Manufacturing Sites & Headquarters
4.6 Global IL-17 Inhibitors for Psoriasis Manufacturers, Product Type & Application
4.7 Global IL-17 Inhibitors for Psoriasis Manufacturers' Establishment Date
4.8 Market Competitive Analysis
4.8.1 Global IL-17 Inhibitors for Psoriasis Market CR5 and HHI
4.8.2 2024 IL-17 Inhibitors for Psoriasis Tier 1, Tier 2, and Tier 3
5 IL-17 Inhibitors for Psoriasis Market by Type
5.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type
5.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2020 VS 2024 VS 2031)
5.1.2 Global IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031) & (US$ Million)
5.1.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Type (2020-2031)
5.2 Global IL-17 Inhibitors for Psoriasis Sales by Type
5.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Type (2020 VS 2024 VS 2031)
5.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031) & (Units)
5.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Type (2020-2031)
5.3 Global IL-17 Inhibitors for Psoriasis Price by Type
6 IL-17 Inhibitors for Psoriasis Market by Application
6.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application
6.1.1 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2020 VS 2024 VS 2031)
6.1.2 Global IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031) & (US$ Million)
6.1.3 Global IL-17 Inhibitors for Psoriasis Revenue Market Share by Application (2020-2031)
6.2 Global IL-17 Inhibitors for Psoriasis Sales by Application
6.2.1 Global IL-17 Inhibitors for Psoriasis Sales by Application (2020 VS 2024 VS 2031)
6.2.2 Global IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031) & (Units)
6.2.3 Global IL-17 Inhibitors for Psoriasis Sales Market Share by Application (2020-2031)
6.3 Global IL-17 Inhibitors for Psoriasis Price by Application
7 Company Profiles
7.1 UCB
7.1.1 UCB Comapny Information
7.1.2 UCB Business Overview
7.1.3 UCB IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.1.4 UCB IL-17 Inhibitors for Psoriasis Product Portfolio
7.1.5 UCB Recent Developments
7.2 Kyowa Kirin
7.2.1 Kyowa Kirin Comapny Information
7.2.2 Kyowa Kirin Business Overview
7.2.3 Kyowa Kirin IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.2.4 Kyowa Kirin IL-17 Inhibitors for Psoriasis Product Portfolio
7.2.5 Kyowa Kirin Recent Developments
7.3 LEO Pharma
7.3.1 LEO Pharma Comapny Information
7.3.2 LEO Pharma Business Overview
7.3.3 LEO Pharma IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.3.4 LEO Pharma IL-17 Inhibitors for Psoriasis Product Portfolio
7.3.5 LEO Pharma Recent Developments
7.4 Ortho Dermatologics
7.4.1 Ortho Dermatologics Comapny Information
7.4.2 Ortho Dermatologics Business Overview
7.4.3 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.4.4 Ortho Dermatologics IL-17 Inhibitors for Psoriasis Product Portfolio
7.4.5 Ortho Dermatologics Recent Developments
7.5 Jiangsu Hengrui Pharmaceuticals
7.5.1 Jiangsu Hengrui Pharmaceuticals Comapny Information
7.5.2 Jiangsu Hengrui Pharmaceuticals Business Overview
7.5.3 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.5.4 Jiangsu Hengrui Pharmaceuticals IL-17 Inhibitors for Psoriasis Product Portfolio
7.5.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
7.6 Eli Lilly
7.6.1 Eli Lilly Comapny Information
7.6.2 Eli Lilly Business Overview
7.6.3 Eli Lilly IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.6.4 Eli Lilly IL-17 Inhibitors for Psoriasis Product Portfolio
7.6.5 Eli Lilly Recent Developments
7.7 Novartis
7.7.1 Novartis Comapny Information
7.7.2 Novartis Business Overview
7.7.3 Novartis IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.7.4 Novartis IL-17 Inhibitors for Psoriasis Product Portfolio
7.7.5 Novartis Recent Developments
7.8 Chongqing Genrix Biopharmaceutical
7.8.1 Chongqing Genrix Biopharmaceutical Comapny Information
7.8.2 Chongqing Genrix Biopharmaceutical Business Overview
7.8.3 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Sales, Revenue, Price and Gross Margin (2020-2025)
7.8.4 Chongqing Genrix Biopharmaceutical IL-17 Inhibitors for Psoriasis Product Portfolio
7.8.5 Chongqing Genrix Biopharmaceutical Recent Developments
8 North America
8.1 North America IL-17 Inhibitors for Psoriasis Market Size by Type
8.1.1 North America IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031)
8.1.2 North America IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031)
8.1.3 North America IL-17 Inhibitors for Psoriasis Price by Type (2020-2031)
8.2 North America IL-17 Inhibitors for Psoriasis Market Size by Application
8.2.1 North America IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031)
8.2.2 North America IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031)
8.2.3 North America IL-17 Inhibitors for Psoriasis Price by Application (2020-2031)
8.3 North America IL-17 Inhibitors for Psoriasis Market Size by Country
8.3.1 North America IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
8.3.2 North America IL-17 Inhibitors for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
8.3.3 North America IL-17 Inhibitors for Psoriasis Price by Country (2020-2031)
8.3.4 United States
8.3.5 Canada
8.3.6 Mexico
9 Europe
9.1 Europe IL-17 Inhibitors for Psoriasis Market Size by Type
9.1.1 Europe IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031)
9.1.2 Europe IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031)
9.1.3 Europe IL-17 Inhibitors for Psoriasis Price by Type (2020-2031)
9.2 Europe IL-17 Inhibitors for Psoriasis Market Size by Application
9.2.1 Europe IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031)
9.2.2 Europe IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031)
9.2.3 Europe IL-17 Inhibitors for Psoriasis Price by Application (2020-2031)
9.3 Europe IL-17 Inhibitors for Psoriasis Market Size by Country
9.3.1 Europe IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
9.3.2 Europe IL-17 Inhibitors for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
9.3.3 Europe IL-17 Inhibitors for Psoriasis Price by Country (2020-2031)
9.3.4 Germany
9.3.5 France
9.3.6 U.K.
9.3.7 Italy
9.3.8 Russia
9.3.9 Spain
9.3.10 Netherlands
10 China
10.1 China IL-17 Inhibitors for Psoriasis Market Size by Type
10.1.1 China IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031)
10.1.2 China IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031)
10.1.3 China IL-17 Inhibitors for Psoriasis Price by Type (2020-2031)
10.2 China IL-17 Inhibitors for Psoriasis Market Size by Application
10.2.1 China IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031)
10.2.2 China IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031)
10.2.3 China IL-17 Inhibitors for Psoriasis Price by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia IL-17 Inhibitors for Psoriasis Market Size by Type
11.1.1 Asia IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031)
11.1.2 Asia IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031)
11.1.3 Asia IL-17 Inhibitors for Psoriasis Price by Type (2020-2031)
11.2 Asia IL-17 Inhibitors for Psoriasis Market Size by Application
11.2.1 Asia IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031)
11.2.2 Asia IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031)
11.2.3 Asia IL-17 Inhibitors for Psoriasis Price by Application (2020-2031)
11.3 Asia IL-17 Inhibitors for Psoriasis Market Size by Country
11.3.1 Asia IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
11.3.2 Asia IL-17 Inhibitors for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
11.3.3 Asia IL-17 Inhibitors for Psoriasis Price by Country (2020-2031)
11.3.4 Japan
11.3.5 South Korea
11.3.6 India
11.3.7 Australia
11.3.8 Taiwan
11.3.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Type
12.1.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue by Type (2020-2031)
12.1.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Type (2020-2031)
12.1.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Type (2020-2031)
12.2 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Application
12.2.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue by Application (2020-2031)
12.2.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Application (2020-2031)
12.2.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Application (2020-2031)
12.3 SAMEA IL-17 Inhibitors for Psoriasis Market Size by Country
12.3.1 SAMEA IL-17 Inhibitors for Psoriasis Revenue Grow Rate by Country (2020 VS 2024 VS 2031)
12.3.2 SAMEA IL-17 Inhibitors for Psoriasis Sales by Country (2020 VS 2024 VS 2031)
12.3.3 SAMEA IL-17 Inhibitors for Psoriasis Price by Country (2020-2031)
12.3.4 Brazil
12.3.5 Argentina
12.3.6 Chile
12.3.7 Colombia
12.3.8 Peru
12.3.9 Saudi Arabia
12.3.10 Israel
12.3.11 UAE
12.3.12 Turkey
12.3.13 Iran
12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
13.1 IL-17 Inhibitors for Psoriasis Value Chain Analysis
13.1.1 IL-17 Inhibitors for Psoriasis Key Raw Materials
13.1.2 Raw Materials Key Suppliers
13.1.3 Manufacturing Cost Structure
13.1.4 IL-17 Inhibitors for Psoriasis Production Mode & Process
13.2 IL-17 Inhibitors for Psoriasis Sales Channels Analysis
13.2.1 Direct Comparison with Distribution Share
13.2.2 IL-17 Inhibitors for Psoriasis Distributors
13.2.3 IL-17 Inhibitors for Psoriasis Customers
14 Concluding Insights
15 Appendix
15.1 Reasons for Doing This Study
15.2 Research Methodology
15.3 Research Process
15.4 Authors List of This Report
15.5 Data Source
15.5.1 Secondary Sources
15.5.2 Primary Sources
15.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.